Select Page

Retinal Protection Sciences

Elegant (adjective): The perfect marriage of form and function; epitomizing simplicity and comprehension; diminished by subtraction or addition; universal, unambiguous, unique; powerful; timelss.

Retinal Protection Sciences, LLC (RPS) is a medical research and development company focused on development of new and innovative technologies and processes for addressing chronic progressive retinopathies (CPRs), the world’s leading causes of irreversible visual loss. 

RPS was founded by Jeffrey K Luttrull, MD in 2016 to commercialize intellectual property (“IP”) developed under his leadership.  For nearly 20 years Dr. Luttrull has been responsible for of groundbreaking advancements in the use of retinal lasers for the restorative and therapeutic treatment of the most important CPRs.  These CPRs are the principle causes of irreversible visual loss today. Because of his innovative work in restorative retinal therapy, Dr. Luttrull is widely recognized as the world’s leading authority on retinal laser treatment. 

RPS is developing a class 2B medical device and system referred to as SAPRA™ (Safe-Pulse™ Retinal Activation™) system.  This laser system integrates the RPS IP and the unparalelled clinical laser experience and database of Dr. Luttrull into a “next generation” therapeutic laser that is specifically designed to acheive absolute treatment safety while maximizing therapeutic effectiveness and efficiency. 

The SAPRA™ system is made up of proprietary confocal scanning laser ophthalmoscope video camera, automated therapeutic laser, and proprietary automated safety technology. This automated safety technology includes groundbreaking adaptive dosimetry technology that is the first to measure retinal pigment density in real-time to perfectly adjust treatment parameters.  As a result, for the first time in the history of retinal laser treatment, the SAPRA system can safely avoid treatment concerns for patients with unusually high or low retinal pigment density.

The SAPRA™ system will be first preventative and therapeutic treatment modality for the most important and widespread causes of irreversible blindness worldwide. These include age-related macular degeneration (AMD), diabetic retinopathy (DR), open angle glaucoma (OAG) and inherited retinal degenerations (IRDs) such as retinitis pigmentosa (RP). SAPRA™ is designed to address these commonalities of these neurodegenerative disease process to reverse progression, improve vision, and prevent visual loss. 

RPS believes that the future of medical care will emphasize disease prevention and functional restoration. SAPRA acheives this through bioactivation, engaging the body’s own fundamental physiologic mechanisms for repair and restoration. 

Elegance: SAPRA™ is the first therapeutic and preventive strategy of any kind to safely and effectively engage the body’s most important and powerful repair and restortaion system, Heat Shock Proteins, for treatment and prevention of chronic progressive diseases and the diseases of ageing, restoring vision and preventing visual loss.  In the eye, we call this Retinal Protective Therapy™ (RPT). The SAPRA system uses patented processes in a highly automated format to deliver RPT optimized for maximum treatment safety, efficacy and comfort and administered in just seconds. SAPRA is thus designed to meet the extraordinary demand of the treatment needs of hundreds of millions of patients and maximize patient acceptance and compliance, the keys to successful prevention. This is SAPRA™ Laser Vision Protection.

RPS anticipates completion of the SAPRA™ system’s regulatory approval in 2020. Many of the SAPRA™ system’s innovative design, use and technologies are patent protected. Issued US patents are listed below. These are supported by international patents in key markets and multiple trademarks :

U.S. Patents Awarded:

1. U.S. Patent. 14/607,959. Luttrull JK, Margolis BWL, Chang DB. Filed January 28, 2015. Issued September 4, 2015. Process for restoring responsiveness to medication in tissue of living organisms.

2. U.S. Patent. 9,381,115. Luttrull JK, Margolis BWL, Chang DB. Entitled: System and process for retina phototherapy. Filed May 12, 2012. Issued July 5, 2016. 

3. U.S. Patent. No. 9,381,116. Luttrull JK, Margolis BWL, Chang DB. Entitled: Subthreshold micropulse laser prophylactic treatment for chronic progressive retinal diseases. Filed: October 23, 2015. Issued July 5, 2016.

4. U.S. Patent. No. 9,427,602.  Pulsating electromagnetic and ultrasound for stimulating targeted heat shock proteins for achieve retinal repair. Filed Oct 26, 2015; issued August 30, 2016.

 5. U.S. Patent. No. 9,962,291 System and process for neuroprotective therapy for glaucoma. Filed: August 9, 2016, awarded May 1, 2018.

6. U.S. Patent. No. 10,076,671 Apparatus for retinal phototherapy.  Filed July 1, 2016; awarded Sept 2018.

7. U.S. Patent. No. 10,117,777 System for neuroprotective therapy for glaucoma. Filed Oct 24, 2018. Awarded Nov 6, 2018.

8. U.S Patent. No. 10,194,798. Measuring RPE and choroid melanin levels with reflectometer.  Filed: November 20, 2017. Awarded: December 18, 2018.  Issued Feb 5, 2019.

9. U.S. Patent. No. 10,219,947. System and process for retina phototherapy. Filed March 13, 2013. Issued March 5, 2019.

10. U.S. Patent No. 10,238,542. System and process for retinal phototherapy. Filed June 6, 2016. Issued March 26, 2019.

11. U.S. Patent No. 10,278,865. Process for neuroprotective therapy for glaucoma. Filed May 3, 2016. Issued May 7, 2019.

12. U.S. Patent No. 10,285,859. System for performing retinal photostimulation. Filed October 22, 2016. Issued May 14, 2019.

13. U.S. Patent No. 10,299,961. System for neuroprotective therapy for glaucoma. Filed April 25, 2018. Issued May 28, 2019.

14. U.S. Patent No. 10,307,294, System and process for neuroprotection in glaucoma. Filed March 29, 2018. Issued June 4, 2019.

15. U.S. Patent No. 10,357,398, System and process for treatment of myopia. Filed November 15, 2017. Issued July 23, 2019

16. U.S. Patent No. 10,363,171, System and process for retinal phototherapy. Filed May 6, 2016. Issued July 30, 2019.

17.U.S. Patent No.10,434,330 Process for safety providing retinal phototherapy by determining retinal melanin levels. Filed January 7, 2019. Issued October 10, 2019.


·         Appropriate protection has been sought for each of these US patents in other key jurisdictions throughout the world. Additionally, there are numerous applications pending that continue, expand and extend the core intellectual property of these patents.


 RPS Principals

Jeffrey K Luttrull, MD    Founder, Chief Executive and Medical Officer

Benjamin WL Margolis, PhD   Chief Engineering Officer

David B Chang, PhD    Chief Scientific Officer

Harry Carneal    Chief of Business Development

Oculox Technologies SAGL  Strategic Engineering and Manufacturing Partner



  • This field is for validation purposes and should be left unchanged.